Back to top

Image: Bigstock

Why The Chemours Company (CC) Isn't Done Growing Earnings Yet

Read MoreHide Full Article

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.

One such company that might be well-positioned for future earnings growth is The Chemours Company (CC - Free Report) .This firm, which is in the Chemical – Diversified industry, saw EPS growth of 29.1% last year, and is looking great for this year too.

In fact, the current growth estimate for this year calls for a significant earnings-per-share growth. Furthermore, the long-term growth rate is currently an impressive 15.5%, suggesting pretty good prospects for the long haul.

Chemours Company (The) Price and Consensus

And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 15.7%. Thanks to this rise in earnings estimates, CC has a Zacks Rank #1 (Strong Buy), which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So if you are looking for a fast growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider CC. Not only does it have double digit earnings growth prospect, but its impressive Zacks Rank suggests that analysts believe better days are ahead for CC as well.

Zacks' Top Investment Ideas for Long-Term Profit

How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


The Chemours Company (CC) - free report >>

Published in